Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.32
- Piotroski Score 2.00
- Grade Buy
- Symbol (AUTL)
- Company Autolus Therapeutics plc
- Price $3.38
- Changes Percentage (1.2%)
- Change $0.04
- Day Low $3.24
- Day High $3.40
- Year High $7.45
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $9.50
- High Stock Price Target $11.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.21
- Trailing P/E Ratio -3.31
- Forward P/E Ratio -3.31
- P/E Growth -3.31
- Net Income $-208,383,000
Income Statement
Quarterly
Annual
Latest News of AUTL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71%
Long-term investing is recommended, but not all stocks should be held forever. Autolus Therapeutics plc (NASDAQ:AUTL) has seen a 71% drop in share price over five years and 21% in the past week....
By Yahoo! Finance | 2 days ago -
Autolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025?
A list of top multibagger penny stocks includes Autolus Therapeutics plc. Autolus focuses on T-cell therapies for cancer and autoimmune diseases. It has strong partnerships and funding, making it a pr...
By Yahoo! Finance | 2 months ago
